ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

VEGF Levels Can Predict Tumor’s Resistance to Avastin

July 29, 2011

NCI Grant To Help Pitt Include Teaching End-of-Life Issues.

July 6, 2001

NCI Advisors Criticize Plan To Fund R01s On ESA Research With Amgen, J&J Money.

June 27, 2008

In Brief: Flood Gives Up Chairmanship, Which Goes to Natcher; Kennedy Hearings Feb. 22-23

February 2, 1979

NCI Programs: Colorectal Cancer Progress Review Group To Assess Research

October 1, 1999

Preoperative Drug Combo Benefits HER-2 Breast Cancer

April 29, 2005